This Day On The Street
Continue to site
ADVERTISEMENT
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here

Allos Therapeutics Reports Fourth Quarter And Full Year 2011 Financial Results

References:

1. The Non-Hodgkin’s Lymphoma Classification Project. A clinical evaluation of the International Lymphoma Study Group classification of non-Hodgkin’s lymphoma. Blood. 1997;89(11):3909-3908.

2. Hennessy BT, Hanrahan EO, Daly PA. Non-Hodgkin lymphoma: an update [review]. Lancet Oncol. 2004;5(6):341-353.

3. O’Leary HM, Savage KJ. Novel therapies in peripheral T-cell lymphomas [review]. Curr Oncol Rep. 2008;134(5):202-207.

4. Savage KJ, Chhanabhai M, Gascoyne RD, et al. Characterization of peripheral T-cell lymphomas in a single North American institution by the WHO classification. Ann Oncol 2004;15(10):1467-75.

5. Savage KJ. Peripheral T-cell Lymphomas. Blood Rev. 2007; 21:201-216.

 
ALLOS THERAPEUTICS, INC.
CONDENSED STATEMENTS OF OPERATIONS
(in thousands, except share and per share information)
(unaudited)
 
  Three Months Ended   Year Ended
December 31, December 31,
2011   2010 2011   2010
Revenue:
Net product sales $ 15,435 $ 11,705 $ 50,486 $ 35,227
License and other revenue   1,476         30,583      
Total revenue 16,911 11,705 81,069 35,227
 
Operating costs and expenses:
Cost of sales, excluding amortization expense 1,293 1,317 4,510 3,647
Cost of license and other revenue 690 11,698
Research and development 4,622 8,303 22,189 31,359
Selling, general and administrative 11,419 21,631 67,817 78,782
Amortization of intangible asset   114     114     454     454  
Total operating costs and expenses   18,138     31,365     106,668     114,242  
Operating loss (1,227 ) (19,660 ) (25,599 ) (79,015 )
Interest and other income, net   11     1,518     85     1,520  
Loss before income taxes (1,216 ) (18,142 ) (25,514 ) (77,495 )
Income tax benefit           7     78  
Net loss   ($1,216 )   ($18,142 )   ($25,507 )   ($77,417 )
Net loss per share: basic and diluted   ($0.01 )   ($0.17 )   ($0.24 )   ($0.74 )
 

Weighted average shares: basic and diluted

  106,029,341     105,373,147     105,711,536     105,123,420  
 
 
ALLOS THERAPEUTICS, INC.
CONDENSED BALANCE SHEETS
(in thousands)
(unaudited)
 
  December 31,   December 31,
2011 2010
ASSETS
Cash, cash equivalents and investments $ 97,772 $ 98,565
Accounts receivable 15,259 12,076
Intangible asset, net 4,772 5,225
Other assets 2,798 2,645
Property and equipment, net   1,476   2,245
Total assets $ 122,077 $ 120,756
LIABILITIES AND STOCKHOLDERS’ EQUITY
Current liabilities, excluding deferred revenue $ 17,443 $ 22,558
Deferred revenue 20,310
Stockholders’ equity   84,324   98,198
Total liabilities and stockholders’ equity $ 122,077 $ 120,756
 




7 of 8

Check Out Our Best Services for Investors

Action Alerts PLUS

Portfolio Manager Jim Cramer and Director of Research Jack Mohr reveal their investment tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
Quant Ratings

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
Stocks Under $10

David Peltier uncovers low dollar stocks with serious upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
14-Days Free
Only $9.95
14-Days Free
Submit an article to us!
SYM TRADE IT LAST %CHG

Markets

DOW 17,958.23 -112.17 -0.62%
S&P 500 2,096.61 -17.88 -0.85%
NASDAQ 4,949.5580 -67.3710 -1.34%

Partners Compare Online Brokers

Free Reports

Top Rated Stocks Top Rated Funds Top Rated ETFs